WO2023016450A1 - 抗tigit抗体及其用途 - Google Patents

抗tigit抗体及其用途 Download PDF

Info

Publication number
WO2023016450A1
WO2023016450A1 PCT/CN2022/111145 CN2022111145W WO2023016450A1 WO 2023016450 A1 WO2023016450 A1 WO 2023016450A1 CN 2022111145 W CN2022111145 W CN 2022111145W WO 2023016450 A1 WO2023016450 A1 WO 2023016450A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
antigen
binding fragment
cancer
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/111145
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
翟天航
黄威锋
戴爽
许英达
布考斯基·约翰
舒茨凯文
黑默莱恩·梅根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotheus Inc
Original Assignee
Biotheus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheus Inc filed Critical Biotheus Inc
Priority to EP22855431.7A priority Critical patent/EP4386003A1/en
Priority to US18/682,325 priority patent/US20240352118A1/en
Priority to KR1020247007621A priority patent/KR20240043786A/ko
Priority to CA3228504A priority patent/CA3228504A1/en
Priority to AU2022327511A priority patent/AU2022327511A1/en
Priority to CN202280054124.0A priority patent/CN117794952A/zh
Priority to JP2024508052A priority patent/JP2024533993A/ja
Publication of WO2023016450A1 publication Critical patent/WO2023016450A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1039—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against T-cell receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to antibodies or antigen-binding fragments thereof that specifically bind to TIGIT and compositions containing the antibodies or antigen-binding fragments thereof.
  • the present invention relates to nucleic acids encoding said antibodies or antigen-binding fragments thereof, host cells comprising them, and related uses.
  • the invention relates to therapeutic and diagnostic uses of these antibodies or antigen-binding fragments thereof.
  • T cell immunoglobulin and ITIM domains T cell immunoreceptor with Ig and ITIM domains, TIGIT, also known as WUCAM, Vstm3, VSIG9
  • TIGIT T cell immunoreceptor with Ig and ITIM domains
  • WUCAM WUCAM
  • Vstm3 VSIG9
  • TIGIT participates in a complex regulatory network in tumor immunity involving multiple immunosuppressive receptors (e.g., CD96/TACTILE, CD112R/PVRIG), a competitive costimulatory receptor (DNAM-1/CD226) and multiple ligands.
  • CD155 PVR/NECL-5
  • CD112 Nectin-2/PVRL2
  • DNAM-1, TIGIT, and CD96 are expressed on T cells and NK cells and share CD155 as a ligand.
  • TIGIT deficiency can delay the growth of B16F10 and MC38 subcutaneous tumors (Kurtulus S, Sakuishi K, Ngiow SF, et al.
  • TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015 Nov 2 ; 125(11):4053-62.). Furthermore, when mice were inoculated with melanoma B16 cells, very few TIGIT-/- mice developed lung metastases compared with mice with normal expression of the TIGIT gene, and the overall survival of TIGIT-/- tumor-bearing mice The period was significantly prolonged (Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018 Jul; 19(7):723-732.). These results suggest that TIGIT plays a key role in tumor immunity as an immunosuppressive receptor.
  • TIGIT-blocking monoclonal antibodies for therapeutic intervention to enhance the activity of T or NK cells to Play anti-tumor effect (Guillerey C, Harjunpaa H, Carrie N, et al. TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma. Blood 2018, 132, 1689–1694.).
  • anti-TIGIT monoclonal antibody can delay the growth of CT26 subcutaneous tumors and methylcholanthracene (MCA)-induced fibroids, and can also protect mice from experimental metastasis of 4T1 or B16 tumors (Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018Jul; 19(7):723-732.).
  • TIGIT is considered to be an attractive target for tumor immunotherapy. Therefore, there is a need in the art to develop new TIGIT antibodies for use in disease treatment, especially cancer treatment.
  • the inventors of the present application obtained a series of anti-TIGIT fully human antibodies, which have high binding affinity to TIGIT, can effectively block the binding of TIGIT to its ligand CD155/CD112, reduce or eliminate the transmission to Inhibitory signals of cells, administration of the antibodies of the present invention can significantly inhibit tumor growth in animal models. Based on this, the present application also provides a composition containing the antibody or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or an antigen-binding fragment thereof, a host cell containing the same, and related uses.
  • the application provides an antibody or an antigen-binding fragment thereof capable of specifically binding to TIGIT, the antibody or an antigen-binding fragment thereof comprising:
  • the variant has one or several amino acid substitutions, deletions or additions (eg 1, 2 or 3 amino acid substitutions, deletions or additions, eg conservative substitutions) compared to the sequence from which it is derived.
  • the substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof comprises: the 3 CDRs contained in the heavy chain variable region (VH) as set forth in SEQ ID NO:4; and/or, as set forth in SEQ ID NO: The three CDRs contained in the light chain variable region (VL) shown in 8.
  • the 3 CDRs contained in the VH and/or the 3 CDRs contained in the VL are defined by the Kabat, IMGT or Chothia numbering system.
  • the antibody or antigen-binding fragment thereof comprises:
  • the CDR is defined by the IMGT numbering system.
  • the antibody or antigen-binding fragment thereof further comprises a framework region of a human immunoglobulin.
  • the antibody or antigen-binding fragment thereof comprises a framework region comprised in the amino acid sequence encoded by a human germline antibody gene. In certain embodiments, the antibody or antigen-binding fragment thereof comprises: a heavy chain framework region contained in an amino acid sequence encoded by a human heavy chain germline gene, and/or an amino acid encoded by a human light chain germline gene The light chain framework region contained in the sequence.
  • the antibody or antigen-binding fragment thereof comprises: a VH comprising a sequence as shown in SEQ ID NO:4 or a variant thereof, and/or, comprising a sequence as shown in SEQ ID NO:8 VL of its variants;
  • the variant has one or several amino acid substitutions, deletions or additions compared to the sequence from which it is derived (for example, 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions) , or have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% , or sequences with 100% sequence identity.
  • the substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof comprises a VH as set forth in SEQ ID NO:4, and/or, a VL as set forth in SEQ ID NO:8.
  • the antibody or antigen-binding fragment thereof is capable of specifically binding to human TIGIT and/or blocking the binding of human TIGIT to its ligand, for example, the binding activity and/or blocking activity is superior to tiragolumab.
  • the antibody or antigen-binding fragment thereof is capable of specifically binding mouse TIGIT and/or blocking the binding of mouse TIGIT to its ligand.
  • the antibody or antigen-binding fragment thereof is cross-reactive with human, cynomolgus and/or mouse TIGIT, e.g., is cross-reactive with human, cynomolgus and mouse TIGIT active.
  • the application provides an antibody or an antigen-binding fragment thereof capable of specifically binding to TIGIT, the antibody or an antigen-binding fragment thereof comprising:
  • the variant has one or several amino acid substitutions, deletions or additions (e.g. 1, 2 or 3 amino acid substitutions, deletions or additions, e.g. conservative substitutions) compared to the sequence from which it is derived.
  • the substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof comprises: the 3 CDRs contained in the heavy chain variable region (VH) as set forth in SEQ ID NO: 12; and/or, as set forth in SEQ ID NO: 16 shows the three CDRs contained in the light chain variable region (VL).
  • the 3 CDRs contained in the VH and/or the 3 CDRs contained in the VL are defined by the Kabat, IMGT or Chothia numbering system.
  • the antibody or antigen-binding fragment thereof comprises:
  • the CDR is defined by the IMGT numbering system.
  • the antibody or antigen-binding fragment thereof further comprises a framework region of a human immunoglobulin.
  • the antibody or antigen-binding fragment thereof comprises a framework region comprised in the amino acid sequence encoded by a human germline antibody gene. In certain embodiments, the antibody or antigen-binding fragment thereof comprises: a heavy chain framework region contained in an amino acid sequence encoded by a human heavy chain germline gene, and/or an amino acid encoded by a human light chain germline gene The light chain framework region contained in the sequence.
  • the antibody or antigen-binding fragment thereof comprises: a VH comprising a sequence as shown in SEQ ID NO: 12 or a variant thereof, and/or, comprising a sequence as shown in SEQ ID NO: 16 VL of its variants;
  • the variant has one or several amino acid substitutions, deletions or additions compared to the sequence from which it is derived (for example, 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions) , or have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% , or sequences with 100% sequence identity.
  • the substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof comprises a VH as set forth in SEQ ID NO:12, and/or, a VL as set forth in SEQ ID NO:16.
  • the antibody or antigen-binding fragment thereof is capable of specifically binding to human TIGIT and/or blocking the binding of human TIGIT to its ligand, for example, the binding activity and/or blocking activity is superior to tiragolumab.
  • the antibody or antigen-binding fragment thereof is cross-reactive with human and cynomolgus TIGIT.
  • the antibodies or antigen-binding fragments thereof of the first and second aspects of the invention further comprise constant regions derived from human immunoglobulins.
  • the heavy chain of the antibody or antigen-binding fragment thereof comprises a human immunoglobulin heavy chain constant region (CH) or a variant thereof having a or multiple amino acid substitutions, deletions or additions (for example, up to 20, up to 15, up to 10, or up to 5 amino acid substitutions, deletions or additions; for example 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions); and/or,
  • CH human immunoglobulin heavy chain constant region
  • the light chain of the antibody or antigen-binding fragment thereof comprises a light chain constant region (CL) of a human immunoglobulin or a variant thereof having conservative substitutions of up to 20 amino acids compared to the sequence from which it is derived ( For example, conservative substitutions of up to 15, up to 10, or up to 5 amino acids; eg, conservative substitutions of 1, 2, 3, 4 or 5 amino acids).
  • CL light chain constant region
  • the variant of the heavy chain constant region (CH) may have a conservative substitution of one or more amino acids compared to the sequence from which it is derived. In such embodiments, the variant of the heavy chain constant region (CH) may have the same or substantially the same effector function as the wild-type sequence from which it is derived.
  • variants of the heavy chain constant region may comprise one or more amino acid mutations or chemical modifications to alter one or more of the following properties of the antibodies of the invention: Fc receptor binding , antibody glycosylation, number of cysteine residues, effector cell function or complement function, etc.
  • Effector function can be altered by substituting at least one amino acid residue in the constant region of the antibody with a different residue or chemically modifying, for example, altering the affinity of the antibody for an effector ligand such as FcR or complement C1q (e.g. decrease or increase).
  • the Fc region of an antibody mediates several important effector functions such as ADCC, phagocytosis, CDC, etc.
  • the antibody or antigen-binding fragment thereof possesses ADCC activity.
  • the antibody or antigen-binding fragment thereof comprises a mutated (e.g., amino acid substitution) or chemically modified Fc region, wherein the mutated or chemically modified Fc region provides an increased ADCC activity.
  • the antibody or antigen-binding fragment thereof is produced by expression in a host cell having low or no fucosylation activity, and the antibody produced has hypofucosylation or afucosylation Glycosylation, thereby increasing its ADCC activity.
  • host cells may be mammalian cells lacking expression of a gene encoding a fucosyltransferase (eg FUT8), eg CHO cells.
  • the heavy chain constant region is an IgG heavy chain constant region, eg, an IgGl, IgG2, IgG3 or IgG4 heavy chain constant region, eg, an IgGl heavy chain constant region.
  • the antibody or antigen-binding fragment thereof is selected from IgG, such as IgG1, IgG2, IgG3 or IgG4.
  • the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain constant region as set forth in SEQ ID NO: 17 or SEQ ID NO: 18.
  • the light chain of the antibody or antigen-binding fragment thereof comprises a light chain constant region derived from a human immunoglobulin (eg, kappa or lambda). In certain exemplary embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain constant region set forth in SEQ ID NO: 22.
  • the antigen-binding fragment is selected from the group consisting of Fab, Fab', (Fab') 2 , Fv, disulfide-linked Fv, scFv, diabody, and single domain antibody (sdAb); and /Or, the antibody is a chimeric antibody, a bispecific antibody or a multispecific antibody.
  • the antibodies of the present invention can be prepared by various methods known in the art, for example, by genetic engineering and recombination techniques. For example, DNA molecules encoding the heavy and light chain genes of the antibodies of the present invention are obtained by chemical synthesis or PCR amplification. The resulting DNA molecule is inserted into an expression vector and then transfected into a host cell. Then, the transfected host cells are cultured under specific conditions, and express the antibody of the present invention.
  • Antigen-binding fragments of the present invention can be obtained by hydrolyzing intact antibody molecules (see Morimoto et al., J. Biochem. Biophys. Methods 24:107-117 (1992) and Brennan et al., Science 229:81 (1985)) . In addition, these antigen-binding fragments can also be directly produced by recombinant host cells (reviewed in Hudson, Curr. Opin. Immunol. 11:548-557 (1999); Little et al., Immunol. Today, 21:364-370 (2000 )).
  • Fab' fragments can be obtained directly from host cells; Fab' fragments can be chemically coupled to form F(ab') 2 fragments (Carter et al., Bio/Technology, 10:163-167 (1992)).
  • Fv, Fab or F(ab') 2 fragments can also be directly isolated from the culture medium of recombinant host cells. Other techniques for preparing these antigen-binding fragments are well known to those of ordinary skill in the art.
  • the application provides an isolated nucleic acid molecule encoding an antibody or antigen-binding fragment thereof, or a heavy chain variable region and/or a light chain variable region thereof, as described above.
  • the isolated nucleic acid molecule comprises a first nucleotide sequence encoding a heavy chain or a heavy chain variable region of an antibody or antigen-binding fragment thereof of the invention and a sequence encoding the antibody or antigen-binding fragment thereof.
  • the isolated nucleic acid molecule of the present invention comprises a second nucleotide sequence comprising the first nucleotide sequence.
  • the present application provides a vector comprising a nucleic acid molecule as described above.
  • the vector is a cloning vector or an expression vector.
  • the vector comprises a first nucleotide sequence encoding a heavy chain or a heavy chain variable region of an antibody of the invention or an antigen-binding fragment thereof and encoding a light chain of the antibody or an antigen-binding fragment thereof Or the second nucleotide sequence of the light chain variable region, wherein said first nucleotide sequence and said second nucleotide sequence are present on the same or different vectors.
  • the vector of the present invention comprises a first vector containing the first nucleotide sequence and a vector containing the A second vector of the second nucleotide sequence.
  • the present application also provides a host cell comprising the nucleic acid molecule or vector as described above.
  • host cells include, but are not limited to, prokaryotic cells such as bacterial cells (such as E. coli cells), and eukaryotic cells such as fungal cells (such as yeast cells), insect cells, plant cells, and animal cells (such as mammalian cells, such as small mouse cells, human cells, etc.).
  • the host cell has low or no fucosylation activity.
  • the host cell may be a mammalian cell lacking expression of a gene encoding a fucosyltransferase (eg, FUT8), eg, a CHO cell.
  • a fucosyltransferase eg, FUT8
  • the present application provides a method for preparing the above-mentioned antibody or antigen-binding fragment thereof, which comprises culturing the above-mentioned host cell under conditions that allow expression of the antibody or antigen-binding fragment thereof, and The antibody or antigen-binding fragment thereof is recovered from cultured host cell culture.
  • the host cell has low or no fucosylation activity, thereby producing a low or no fucosylation antibody to enhance the ADCC activity of the antibody produced therein.
  • the host cell may be a mammalian cell lacking expression of a gene encoding a fucosyltransferase (eg, FUT8), eg, a CHO cell.
  • the present application provides a pharmaceutical composition
  • a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, an isolated nucleic acid molecule, a vector or a host cell as described above, and a pharmaceutically acceptable carrier and/or excipient.
  • the pharmaceutical composition further comprises an additional immune checkpoint inhibitor.
  • the pharmaceutical composition further comprises an anti-PD-1 antibody or an anti-PD-L1 antibody.
  • the pharmaceutically acceptable carrier and/or excipient comprises a sterile injectable liquid (eg, aqueous or non-aqueous suspension or solution).
  • a sterile injectable liquid eg, aqueous or non-aqueous suspension or solution.
  • sterile injectable liquids are selected from the group consisting of water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (eg 0.9% (w/v) NaCl), dextrose solutions (eg, 5% dextrose), solutions containing surfactants (eg, 0.01% polysorbate 20), pH buffered solutions (eg, phosphate buffered saline), Ringer's solutions, and any combination thereof.
  • WFI water for injection
  • BWFI bacteriostatic water for injection
  • sodium chloride solution eg 0.9% (w/v) NaCl
  • dextrose solutions eg, 5% dextrose
  • surfactants eg, 0.01% polysorb
  • the present application provides the above-mentioned antibody or antigen-binding fragment thereof, isolated nucleic acid molecule, vector, host cell or pharmaceutical composition for the use of the preparation of a medicament, and the medicament is used for:
  • the immune cells are T cells, and/or, NK cells.
  • the immune response is a T cell or NK cell mediated immune response.
  • the tumor involves TIGIT-positive infiltrating T cells and/or NK cells, and/or involves TIGIT ligand (eg, CD155 and/or CD112)-positive tumor cells.
  • TIGIT ligand eg, CD155 and/or CD112
  • the tumor is selected from solid tumors or hematological tumors (eg, leukemia, lymphoma, myeloma).
  • hematological tumors eg, leukemia, lymphoma, myeloma
  • the tumor is selected from the group consisting of colorectal cancer, colon cancer, bladder cancer, breast cancer, uterine/cervical cancer, ovarian cancer, prostate cancer, testicular cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, renal Cancer, head and neck cancer, lung cancer, gastric cancer, germ cell cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, tumors of the central nervous system, lymphoma, leukemia, myeloma, sarcoma, melanoma.
  • the infection is selected from a viral infection, a bacterial infection, a fungal infection, and a parasitic infection.
  • the subject is a mammal, such as a human, cynomolgus monkey, or mouse.
  • the antibody or antigen-binding fragment thereof, isolated nucleic acid molecule, vector, host cell, or pharmaceutical composition is used alone or in combination with another pharmaceutically active agent.
  • the additional pharmaceutically active agent is an additional immune checkpoint inhibitor.
  • the antibody or antigen-binding fragment thereof, isolated nucleic acid molecule, vector, host cell or pharmaceutical composition is used in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody.
  • the present application provides a method for enhancing immune response or preventing and/or treating tumor or infection in a subject, comprising: administering to a subject in need thereof an effective amount of the above-mentioned Antibodies or antigen-binding fragments thereof or pharmaceutical compositions.
  • the tumor involves TIGIT-positive infiltrating T cells and/or NK cells, and/or involves TIGIT ligand (eg, CD155 and/or CD112)-positive tumor cells.
  • TIGIT ligand eg, CD155 and/or CD112
  • the tumor is selected from solid tumors or hematological tumors (eg, leukemia, lymphoma, myeloma).
  • hematological tumors eg, leukemia, lymphoma, myeloma
  • the tumor is selected from the group consisting of colorectal cancer, colon cancer, bladder cancer, breast cancer, uterine/cervical cancer, ovarian cancer, prostate cancer, testicular cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, renal Cancer, head and neck cancer, lung cancer, gastric cancer, germ cell cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, tumors of the central nervous system, lymphoma, leukemia, myeloma, sarcoma, melanoma.
  • the infection is selected from a viral infection, a bacterial infection, a fungal infection, and a parasitic infection.
  • the subject is a mammal, such as a human.
  • the antibody or antigen-binding fragment thereof or the pharmaceutical composition of the present application can be formulated into any dosage form known in the medical field, for example, tablets, pills, suspensions, emulsions, solutions, gels, capsules, powders, granules , elixirs, lozenges, suppositories, injections (including injections, sterile powders for injections and concentrated solutions for injections), inhalants, sprays, etc.
  • the preferred dosage form depends on the intended mode of administration and therapeutic use.
  • Antibodies or antigen-binding fragments thereof or pharmaceutical compositions of the invention should be sterile and stable under the conditions of manufacture and storage.
  • a preferred dosage form is injection. Such injections can be sterile injectable solutions.
  • sterile injectable solutions can be prepared by incorporating in an appropriate solvent the necessary dose of an antibody or antigen-binding fragment thereof of the present invention and, optionally, concomitantly incorporating other desired ingredients including, but not limited to pH adjusters, surfactants, adjuvants, ionic strength enhancers, isotonic agents, preservatives, diluents, or any combination thereof), followed by filter sterilization.
  • sterile injectable solutions can be prepared as sterile lyophilized powder (eg, by vacuum drying or freeze-drying) for ease of storage and use.
  • Such sterile lyophilized powders can be dispersed in suitable carriers before use, such as water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (such as 0.9% (w/v) NaCl), Dextrose solution (eg 5% glucose), surfactant containing solution (eg 0.01% polysorbate 20), pH buffered solution (eg phosphate buffered saline), Ringer's solution and any combination thereof.
  • WFI water for injection
  • BWFI bacteriostatic water for injection
  • sodium chloride solution such as 0.9% (w/v) NaCl
  • Dextrose solution eg 5% glucose
  • surfactant containing solution eg 0.01% polysorbate 20
  • pH buffered solution eg phosphate buffered saline
  • Ringer's solution any combination thereof.
  • the antibody or antigen-binding fragment thereof of the present application, or the pharmaceutical composition of the present invention can be administered by any suitable method known in the art, including but not limited to, oral, oral, sublingual, ophthalmic, topical, parenteral, Rectal, intrathecal, intracytoplasmic reticulum, inguinal, intravesical, topical (eg, powder, ointment, or drops), or nasal routes.
  • the preferred route/mode of administration is parenteral (eg, intravenous or bolus injection, subcutaneous injection, intraperitoneal injection, intramuscular injection).
  • an antibody or antigen-binding fragment thereof or pharmaceutical composition of the invention is administered by intravenous injection or bolus injection.
  • the application provides a conjugate comprising an antibody or antigen-binding fragment thereof as described above, and a detectable label linked to the antibody or antigen-binding fragment thereof.
  • the detectable label is selected from enzymes (such as horseradish peroxidase or alkaline phosphatase), chemiluminescence reagents (such as acridinium esters, luminol and its derivatives, or ruthenium derivatives), fluorescent dyes (such as fluorescein or fluorescent protein), radionuclides or biotin.
  • enzymes such as horseradish peroxidase or alkaline phosphatase
  • chemiluminescence reagents such as acridinium esters, luminol and its derivatives, or ruthenium derivatives
  • fluorescent dyes such as fluorescein or fluorescent protein
  • the present application provides a kit comprising the antibody or antigen-binding fragment thereof or the conjugate as described above.
  • the kit comprises a conjugate as described above.
  • the kit comprises an antibody or antigen-binding fragment thereof as described above, and a second antibody that specifically recognizes said antibody or antigen-binding fragment thereof.
  • the second antibody further includes a detectable label, such as an enzyme (such as horseradish peroxidase or alkaline phosphatase), a chemiluminescent reagent (such as acridinium esters, luminol and its derivatives, or ruthenium derivatives), fluorescent dyes (such as fluorescein or fluorescent protein), radionuclides or biotin.
  • an enzyme such as horseradish peroxidase or alkaline phosphatase
  • a chemiluminescent reagent such as acridinium esters, luminol and its derivatives, or ruthenium derivatives
  • fluorescent dyes such as fluorescein or fluorescent protein
  • the present application provides a method for detecting the presence or level of TIGIT in a sample comprising using an antibody or antigen-binding fragment thereof as described above or a conjugate as described above.
  • the methods are used for therapeutic purposes, diagnostic purposes, or non-therapeutic non-diagnostic purposes.
  • the method is an immunological assay, such as a western blot, an enzyme immunoassay (eg, ELISA), a chemiluminescent immunoassay, a fluorescent immunoassay, or a radioimmunoassay.
  • the method comprises using a conjugate as described above.
  • the method comprises the use of an antibody or antigen-binding fragment thereof as described above, and the method further comprises the use of an antibody carrying a detectable label (e.g., an enzyme such as horseradish peroxidase or alkaline phosphate enzymes), chemiluminescent reagents (such as acridinium esters, luminol and its derivatives, or ruthenium derivatives), fluorescent dyes (such as fluorescein or fluorescent protein), radionuclides or biotin) secondary antibodies to detect the antibody or antigen-binding fragment thereof.
  • a detectable label e.g., an enzyme such as horseradish peroxidase or alkaline phosphate enzymes
  • chemiluminescent reagents such as acridinium esters, luminol and its derivatives, or ruthenium derivatives
  • fluorescent dyes such as fluorescein or fluorescent protein
  • the method comprises: (1) contacting the sample with an antibody of the invention or an antigen-binding fragment thereof; (2) detecting the formation of an antigen-antibody immune complex or detecting the immune complex amount.
  • the formation of such immune complexes indicates the presence of TIGIT or cells expressing TIGIT.
  • the present application also provides the use of the above-mentioned antibody or its antigen-binding fragment or the above-mentioned conjugate in the preparation of a detection reagent, and the kit is used to detect the presence of TIGIT in a sample or its level.
  • the detection reagent detects the presence or level of TIGIT in a sample by a method as described above.
  • the sample is a sample of cells (eg, immune cells) from a subject (eg, a mammal, preferably a human, cynomolgus monkey or mouse).
  • a subject eg, a mammal, preferably a human, cynomolgus monkey or mouse.
  • antibody refers to an immunoglobulin molecule, usually composed of two pairs of polypeptide chains, each pair having one light chain (LC) and one heavy chain (HC).
  • Antibody light chains can be classified as kappa (kappa) and lambda (lambda) light chains.
  • Heavy chains can be classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively.
  • the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also comprising a "D" region of about 3 or more amino acids.
  • Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (CH).
  • the heavy chain constant region consists of 3 domains (CH1, CH2 and CH3).
  • Each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL).
  • the light chain constant region consists of one domain, CL.
  • the constant domains are not directly involved in antibody-antigen binding, but exhibit a variety of effector functions, such as mediating immunoglobulin interactions with host tissues or factors, including various cells of the immune system (e.g., effector cells) and classical complement Binding of the first component (C1q) of the system.
  • VH and VL regions can also be subdivided into regions of high variability called complementarity determining regions (CDRs) interspersed with more conserved regions called framework regions (FRs).
  • CDRs complementarity determining regions
  • FRs framework regions
  • Each VH and VL consists of 3 CDRs and 4 FRs arranged in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4, from amino-terminus to carboxy-terminus.
  • the variable regions (VH and VL) of each heavy chain/light chain pair form the antigen binding site, respectively.
  • the allocation of amino acids in each region or domain can follow Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987and 1991)), or Chothia & Lesk (1987) J.Mol.Biol.196:901- 917; Definition by Chothia et al. (1989) Nature 342:878-883.
  • CDR complementarity determining region
  • the variable regions of the heavy and light chains each contain three CDRs, designated CDR1, CDR2 and CDR3.
  • CDR1, CDR2 and CDR3 The precise boundaries of these CDRs can be defined according to various numbering systems known in the art, such as the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), the Chothia numbering system (Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; Chothia et al.
  • the CDRs contained in the antibody of the present invention or an antigen-binding fragment thereof can be determined according to various numbering systems known in the art.
  • antibodies of the invention or antigen-binding fragments thereof contain CDRs preferably identified by the Kabat, Chothia or IMGT numbering system.
  • antibodies of the invention or antigen-binding fragments thereof contain CDRs preferably identified by the IMGT numbering system.
  • framework region or "FR” residues refers to those amino acid residues in an antibody variable region other than the CDR residues as defined above.
  • antibody is not limited to any particular method of producing antibodies. For example, it includes recombinant antibodies, monoclonal antibodies and polyclonal antibodies. Antibodies can be of different isotypes, eg, IgG (eg, IgGl, IgG2, IgG3, or IgG4 subtype), IgAl, IgA2, IgD, IgE, or IgM antibodies.
  • IgG eg, IgGl, IgG2, IgG3, or IgG4 subtype
  • IgAl IgA2, IgD, IgE, or IgM antibodies.
  • the term "antigen-binding fragment" of an antibody refers to a polypeptide comprising a fragment of a full-length antibody that retains the ability to specifically bind to the same antigen to which the full-length antibody binds, and/or competes with the full-length antibody for Specific binding to an antigen, which is also referred to as an "antigen-binding moiety".
  • an antigen-binding moiety See generally, Fundamental Immunology, Ch.7 (Paul, W., ed., 2nd ed., Raven Press, NY (1989), which is incorporated herein by reference in its entirety for all purposes. Can be obtained by recombinant DNA techniques. or by enzymatic or chemical cleavage of intact antibodies to generate antigen-binding fragments of antibodies.
  • Non-limiting examples of antigen-binding fragments include Fab, Fab', F(ab') 2 , Fd, Fv, complementarity determining region (CDR) fragments, scFv, diabody, single domain antibody, chimeric antibody, linear antibody, nanobody (technology from Domantis), probody, and polypeptides comprising sufficient At least a portion of an antibody of antigen binding capacity.
  • Engineered antibody variants are reviewed in Holliger et al., 2005; Nat Biotechnol, 23:1126-1136.
  • full-length antibody means an antibody consisting of two “full-length heavy chains” and two “full-length light chains”.
  • “full-length heavy chain” refers to such a polypeptide chain, which consists of a heavy chain variable region (VH), a heavy chain constant region CH1 domain, a hinge region (HR), a heavy chain The CH2 domain of the constant region and the CH3 domain of the constant region of the heavy chain; and, when the full-length antibody is of the IgE isotype, optionally further includes the CH4 domain of the constant region of the heavy chain.
  • a "full-length heavy chain” is a polypeptide chain consisting of VH, CH1, HR, CH2 and CH3 in the N-terminal to C-terminal direction.
  • a "full-length light chain” is a polypeptide chain consisting, in the N-terminal to C-terminal direction, of a light chain variable region (VL) and a light chain constant region (CL).
  • VL light chain variable region
  • CL light chain constant region
  • the two pairs of full-length antibody chains are linked together by a disulfide bond between CL and CH1 and between the HRs of the two full-length heavy chains.
  • the full-length antibody of the present invention can be from a single species, such as human; it can also be a chimeric antibody or a humanized antibody.
  • the full-length antibody of the present invention comprises two antigen-binding sites respectively formed by VH and VL pairs, and these two antigen-binding sites specifically recognize/bind to the same antigen.
  • the term “Fd” means an antibody fragment consisting of VH and CH1 domains
  • the term “dAb fragment” means an antibody fragment consisting of a VH domain (Ward et al., Nature 341:544 546( 1989))
  • the term “Fab fragment” means an antibody fragment consisting of VL, VH, CL and CH1 domains
  • the term “F(ab') 2 fragment” means a fragment comprising two An antibody fragment of a Fab fragment
  • the term “Fab'fragment” means the fragment obtained after reduction of the disulfide bond linking the two heavy chain fragments in the F(ab') 2 fragment, consisting of an intact light chain and the Fd of the heavy chain Fragment (consisting of VH and CH1 domains).
  • the term "Fv" means an antibody fragment consisting of the VL and VH domains of a single arm of an antibody.
  • the Fv fragment is generally considered to be the smallest antibody fragment capable of forming a complete antigen-binding site. It is generally believed that the six CDRs confer antigen-binding specificity to an antibody. However, even a variable region (such as the Fd fragment, which contains only three CDRs specific for an antigen) is able to recognize and bind antigen, although perhaps with a lower affinity than the full binding site.
  • Fc means that the second and third constant regions of the first heavy chain of an antibody are combined with the second and third constant regions of the second heavy chain via disulfide bonds.
  • Antibody fragments The Fc fragment of an antibody has a variety of different functions, but is not involved in antigen binding.
  • scFv refers to a single polypeptide chain comprising VL and VH domains, wherein the VL and VH are linked by a linker (see, e.g., Bird et al., Science 242:423 -426 (1988); Huston et al, Proc. New York, pp. 269-315 (1994)).
  • linker see, e.g., Bird et al., Science 242:423 -426 (1988); Huston et al, Proc. New York, pp. 269-315 (1994)).
  • Such scFv molecules may have the general structure: NH2 -VL-linker-VH-COOH or NH2 -VH-linker-VL-COOH.
  • Suitable prior art linkers consist of the repeated GGGGS amino acid sequence or variants thereof.
  • a linker having the amino acid sequence (GGGGS) 4 can be used, but variants thereof can also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90:6444-6448).
  • Other linkers useful in the present invention are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur.J. Immunol.31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, described by Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001) Cancer Immunol.
  • scFv can form di-scFv, which refers to two or more single scFv connected in series to form an antibody.
  • scFv can form (scFv) 2 , which refers to the parallel connection of two or more single scFv to form an antibody.
  • the term "diabody” means that its VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow pairing between the two domains of the same chain, This forces the domain to pair with the complementary domain of another chain and creates two antigen-binding sites (see, e.g., Holliger P. et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993), and Poljak R.J. et al., Structure 2:1121-1123 (1994)).
  • single-domain antibody has the meaning commonly understood by those skilled in the art, which refers to a single monomer variable antibody domain (such as a single heavy chain variable antibody domain) region) that retains the ability to specifically bind the same antigen to which the full-length antibody binds.
  • Single domain antibodies are also called nanobodies.
  • Each of the above antibody fragments maintains the ability to specifically bind to the same antigen to which the full-length antibody binds, and/or competes with the full-length antibody for specific binding to the antigen.
  • Antigen-binding fragments of antibodies can be obtained from a given antibody (e.g., an antibody provided herein) using conventional techniques known to those skilled in the art (e.g., recombinant DNA techniques or enzymatic or chemical cleavage methods) ), and antigen-binding fragments of antibodies are screened for specificity in the same manner as for whole antibodies.
  • antibody includes not only whole antibodies but also antigen-binding fragments of antibodies.
  • the term "Chimeric antibody” refers to an antibody whose light chain and/or heavy chain are partly derived from an antibody (which may be derived from a particular species or belong to a certain a specific antibody class or subclass), and the other part of the light chain or/and heavy chain is derived from another antibody (which may be derived from the same or different species or belong to the same or different antibody class or subclass), but regardless However, it still retains the binding activity to the target antigen (U.S.P 4,816,567 to Cabilly et al.; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851 6855 (1984)).
  • the term “chimeric antibody” may include antibodies in which the antibody's heavy and light chain variable regions are derived from a first antibody and the antibody's heavy and light chain constant regions are derived from a second antibody.
  • the term "identity" is used to refer to the match of sequences between two polypeptides or between two nucleic acids.
  • the sequences are aligned for optimal comparison purposes (for example, gaps may be introduced in a first amino acid sequence or nucleic acid sequence to best align with a second amino acid or nucleic acid sequence).
  • Jiabi pair The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
  • the determination of percent identity between two sequences can also be accomplished using a mathematical algorithm.
  • a non-limiting example of a mathematical algorithm for the comparison of two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Modified from .Acad.Sci.U.S.A. 90:5873-5877. Such an algorithm was incorporated into the NBLAST and XBLAST programs of Altschul et al., 1990, J. Mol. Biol. 215:403.
  • variant in the context of polypeptides (including polypeptides), also refers to a polypeptide or peptide comprising an amino acid sequence that has been altered by introducing amino acid residue substitutions, deletions or additions. In certain instances, the term “variant” also refers to a polypeptide or peptide that has been modified (ie, by covalently linking molecules of any type to the polypeptide or peptide).
  • polypeptides may be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, Attachment to cellular ligands or other proteins, etc.
  • Derivative polypeptides or peptides can be produced by chemical modification using techniques known to those skilled in the art, including but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, and the like.
  • a variant has a similar, identical or improved function to the polypeptide or peptide from which it is derived.
  • the term "specific binding” refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and its antigen.
  • the strength or affinity of a specific binding interaction can be expressed in terms of the equilibrium dissociation constant ( KD ) for that interaction.
  • KD refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between an antibody and an antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding, and the higher the affinity between the antibody and the antigen.
  • the specific binding properties between two molecules can be determined using methods well known in the art.
  • One method involves measuring the rate of antigen binding site/antigen complex formation and dissociation.
  • Both the "association rate constant” (ka or kon) and the “dissociation rate constant” (kdis or koff) can be calculated from the concentration and actual rates of association and dissociation (see Malmqvist M, Nature, 1993, 361 :186-187).
  • the ratio kdis/kon is equal to the dissociation constant KD (see Davies et al., Annual Rev Biochem, 1990; 59:439-473).
  • KD , kon and kdis values can be measured by any effective method.
  • dissociation constants can be measured in Biacore using surface plasmon resonance (SPR).
  • bioluminescent interferometry or Kinexa can be used to measure dissociation constants.
  • a detectable label according to the invention can be any substance detectable by fluorescent, spectroscopic, photochemical, biochemical, immunological, electrical, optical or chemical means.
  • labels are well known in the art, examples of which include, but are not limited to, enzymes (e.g., horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, urease, glucose oxidase, etc.), radionuclide Chlorin (for example, 3 H, 125 I, 35 S, 14 C or 32 P), fluorescent dyes (for example, fluorescein isothiocyanate (FITC), fluorescein, tetramethylrhodamine isothiocyanate (TRITC) , phycoerythrin (PE), Texas Red, rhodamine, quantum dots or cyanine dye derivatives (such as Cy7, Alexa750)), luminescent substances (such as chemiluminescent substances, such as acridinium ester
  • vector refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted.
  • the vector is called an expression vector.
  • a vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries can be expressed in the host cell.
  • Vectors are well known to those skilled in the art, including but not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC) ; Phage such as lambda phage or M13 phage and animal viruses.
  • artificial chromosomes such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC)
  • Phage such as lambda phage or M13 phage and animal viruses.
  • Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomaviruses, papillomaviruses, Polyoma vacuolar virus (eg SV40).
  • a vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes.
  • the vector may also contain an origin of replication.
  • the term "host cell” refers to cells that can be used to introduce vectors, including, but not limited to, prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, Insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
  • prokaryotic cells such as Escherichia coli or Bacillus subtilis
  • fungal cells such as yeast cells or Aspergillus
  • Insect cells such as S2 Drosophila cells or Sf9
  • animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
  • conservative substitution means an amino acid substitution that does not adversely affect or alter the expected properties of the protein/polypeptide comprising the amino acid sequence.
  • conservative substitutions can be introduced by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • Conservative amino acid substitutions include substitutions for amino acid residues with amino acid residues that have similar side chains, e.g., are physically or functionally similar (e.g., have similar size, shape, charge, chemical properties, including Substitution of residues with the ability to form covalent or hydrogen bonds, etc.). Families of amino acid residues having similar side chains have been defined in the art.
  • These families include those with basic side chains (e.g., lysine, arginine, and histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine) , asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (such as alanine, valine, leucine, isoleucine amino acid, proline, phenylalanine, methionine), beta branched side chains (e.g. threonine, valine, isoleucine) and aromatic side chains (e.g.
  • basic side chains e.g., lysine, arginine, and histidine
  • acidic side chains e.g., aspartic acid, glutamic acid
  • uncharged polar side chains e.g., glycine
  • non-polar side chains such as
  • the term "pharmaceutically acceptable carrier and/or excipient” refers to a carrier and/or excipient compatible with the subject and the active ingredient pharmacologically and/or physiologically, These are well known in the art (see e.g. Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and include, but are not limited to: pH adjusters, surfactants, adjuvants, ionic strength enhancers agents, diluents, agents to maintain osmotic pressure, agents to delay absorption, preservatives.
  • pH adjusting agents include, but are not limited to, phosphate buffers.
  • Surfactants include but are not limited to cationic, anionic or nonionic surfactants such as Tween-80.
  • Ionic strength enhancers include, but are not limited to, sodium chloride.
  • Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • Agents to maintain osmotic pressure include, but are not limited to, sugars, NaCl, and the like.
  • Agents that delay absorption include, but are not limited to, monostearates and gelatin.
  • Diluents include, but are not limited to, water, aqueous buffers (eg, buffered saline), alcohols and polyols (eg, glycerol), and the like.
  • Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as thimerosal, 2-phenoxyethanol, parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • Stabilizer has the meaning generally understood by those skilled in the art, and it can stabilize the desired activity of the active ingredient in the medicine, including but not limited to sodium glutamate, gelatin, SPGA, sugars (such as sorbitol, mannitol, starch, sucrose , lactose, dextran, or glucose), amino acids (such as glutamic acid, glycine), proteins (such as dry whey, albumin or casein) or their degradation products (such as lactalbumin hydrolyzate), etc.
  • the pharmaceutically acceptable carrier or excipient comprises a sterile injectable liquid (eg, aqueous or non-aqueous suspension or solution).
  • such sterile injectable liquids are selected from the group consisting of water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (eg 0.9% (w/v) NaCl), dextrose solutions (eg, 5% dextrose), solutions containing surfactants (eg, 0.01% polysorbate 20), pH buffered solutions (eg, phosphate buffered saline), Ringer's solutions, and any combination thereof.
  • WFI water for injection
  • BWFI bacteriostatic water for injection
  • sodium chloride solution eg 0.9% (w/v) NaCl
  • dextrose solutions eg, 5% dextrose
  • solutions containing surfactants eg, 0.01% polysorbate 20
  • pH buffered solutions eg, phosphate buffered saline
  • Ringer's solutions e.g, Ringer's solutions, and any combination thereof.
  • prevention refers to methods performed to prevent or delay the occurrence of a disease or disorder or symptom in a subject.
  • treatment refers to a method performed to obtain a beneficial or desired clinical result.
  • a beneficial or desired clinical outcome includes, but is not limited to, relief of symptoms, reduction of the extent of the disease, stabilization (i.e., no longer worsening) of the disease state, delay or slowing of the progression of the disease, amelioration or palliation of the disease status, and relief of symptoms (whether partial or total), whether detectable or undetectable.
  • treating can also refer to prolonging survival as compared to expected survival if not receiving treatment.
  • the term "subject” refers to mammals, such as humans, cynomolgus monkeys, mice.
  • the subject e.g., human, cynomolgus monkey, mouse
  • has a TIGIT-associated disease e.g., involving TIGIT-positive infiltrating T cells and/or NK cells, and/or Tumors involving tumor cells positive for TIGIT ligands (eg, CD155 and/or CD112), or, at risk of having the above diseases.
  • an effective amount refers to an amount sufficient to achieve, or at least partially achieve, the desired effect.
  • an effective amount for preventing a disease for example, involving TIGIT positive infiltrating T cells and/or NK cells, and/or involving TIGIT ligand (such as CD155 and/or CD112) positive tumor cells
  • an effective amount for treating the disease refers to an amount sufficient to cure or at least partially prevent the disease and its complications in a patient already suffering from the disease. Determining such an effective amount is well within the capability of those skilled in the art.
  • amounts effective for therapeutic use will depend on the severity of the disease to be treated, the general state of the patient's own immune system, the general condition of the patient such as age, weight and sex, the mode of administration of the drug, and other treatments administered concomitantly etc.
  • the present invention provides a fully human antibody against TIGIT, which has a high binding affinity to TIGIT, can effectively block the binding of TIGIT to its ligand CD155/CD112, reduce or eliminate the inhibitory signal transmitted to cells, and can be administered in animal models
  • the antibodies of the present invention can significantly inhibit tumor growth. Therefore, the antibodies of the present invention can be used for various purposes, including but not limited to enhancing immune response, inhibiting tumor growth, anti-infection and detecting TIGIT protein.
  • the fully human antibodies of the present invention can be safely administered to human subjects without eliciting immunogenic responses. Therefore, the antibodies of the present invention have great clinical value.
  • Fig. 1 shows the binding activity of the anti-TIGIT antibody of the present invention to human TIGIT overexpressed on CHO cells.
  • Figure 2 shows the binding activity of the anti-TIGIT antibody of the present invention to cynomolgus monkey TIGIT overexpressed on CHO cells.
  • Fig. 3 shows the binding activity of the anti-TIGIT antibody of the present invention to mouse TIGIT overexpressed on CHO cells.
  • Figure 4 shows the blocking activity of anti-TIGIT antibodies of the present invention to block the binding of human CD155 to human TIGIT overexpressed on CHO cells.
  • Figure 5 shows the blocking activity of the anti-TIGIT antibody of the present invention to block the binding of mouse CD155 to mouse TIGIT overexpressed on CHO cells.
  • Fig. 6 shows the binding activity of the anti-TIGIT antibody of the present invention to TIGIT on activated human primary T cells.
  • Fig. 7 shows the blocking activity of the anti-TIGIT antibody monoclonal antibody molecules of the present invention to block the TIGIT/CD155 signaling pathway.
  • Figures 8A-8B show that the anti-TIGIT antibody of the present invention cooperates with anti-PD-L1/PD-1 molecules to block TIGIT/CD155/CD112, the blocking activity of PD-L1/PD-1 signaling pathway.
  • Figures 9A-C show the in vitro ADCC activity of anti-TIGIT antibodies of the invention.
  • 10A-B show the pharmacodynamic study of the anti-TIGIT antibody of the present invention in the wild-type mouse CT-26 tumor model.
  • Figure 11 shows the synergistic pharmacodynamic study of the anti-TIGIT antibody of the present invention and the anti-PD-L1 antibody in the wild-type mouse CT-26 tumor model.
  • Figure 12A-B shows the synergistic pharmacodynamic study of the anti-TIGIT antibody of the present invention and the anti-PD-L1 antibody in the huTIGIT KI mouse CT-26 tumor model.
  • Figure 13 shows the synergistic pharmacodynamic study of the anti-TIGIT antibody of the present invention and the anti-PD-L1 antibody in the B-NDG mouse model inoculated with A375 and human PBMC.
  • Figures 14A-B show half-life studies of anti-TIGIT antibodies of the invention in mice.
  • the molecular biology experiment methods and immunoassay methods used in the present invention are basically with reference to J.Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, and F.M.Ausubel et al., Compiled Molecular Biology Experimental Guide, 3rd Edition, John Wiley & Sons, Inc., 1995 by the method described; restriction endonucleases were used in accordance with the conditions recommended by the product manufacturer.
  • restriction endonucleases were used in accordance with the conditions recommended by the product manufacturer.
  • yeast antibody display library (Adimab) Based on the yeast antibody display library (Adimab), amplification was performed according to existing methods (see patent applications WO2009036379, WO2010105256 and WO2012009568), wherein the diversity of each library reached 1 ⁇ 10 9 . Briefly, the first two rounds of screening were performed using Miltenyi's MACS system for magnetic bead cell sorting. First, incubate the yeast cells in the library ( ⁇ 1 ⁇ 10 10 cells/library) in FACS washing buffer (phosphate buffered saline containing 0.1% BSA) for 15 minutes at room temperature, and the buffer contains 100 nM biotin-labeled human TIGIT antigen (purchased from Acro, Cat. No.: TIT-H5254).
  • FACS washing buffer phosphate buffered saline containing 0.1% BSA
  • the culture medium was discarded, and after the cells were washed twice with FACS washing buffer, the cells were mixed with LC-FITC (FITC-labeled anti-human immunoglobulin kappa light chain antibody, purchased from Southern Biotech) (1:100 dilution), and Mix with SA-633 (Streptavidin-633, purchased from Molecular Probes) (1:500 dilution) or SA-PE (Streptavidin-PE, purchased from Sigma) (1:50 dilution), 40 Incubate for 15 minutes at °C. Elute twice with pre-cooled FACS wash buffer and resuspend in 0.4 mL of buffer, transfer the cells to a separation tube with filter. Cells were sorted using FACS ARIA (BD Biosciences).
  • yeast cells obtained by screening were shaken and induced at 30°C for 48 hours to secrete and express the target anti-TIGIT antibody (full-length IgG). After the induction, yeast cells were removed by centrifugation at 1300 rpm for 10 minutes, and the supernatant was harvested. Purify the anti-TIGIT antibody in the supernatant using Protein A, elute with pH 2.0 acetic acid solution, and harvest the anti-TIGIT antibody.
  • the CDRH3 gene of the parent molecule was constructed into a 1 ⁇ 10 8 diversity CDRH1/CDRH2 gene library, and three rounds of screening were performed on it.
  • the MACS method was used in the first round, and the FACS method was used in the second and third rounds to pressurize the affinity of the antibody-antigen conjugate and screen out high-affinity antibodies.
  • the yeast cells obtained by screening and expressing anti-TIGIT antibody were shaken and cultured at 30°C for 48 hours to produce TIGIT antibody. After the induced expression was completed, the yeast cells were removed by centrifugation at 1300 rpm for 10 minutes, and the supernatant was harvested.
  • the anti-TIGIT antibody in the supernatant was purified using Protein A, eluted with pH 2.0 acetic acid solution, and the anti-TIGIT antibody was harvested.
  • the corresponding Fab fragments were obtained using papain and purified with KappaSelect (GE Life Medical Group).
  • the method is to introduce mutations into the heavy chain region by conventional mismatch PCR method.
  • the base mismatch probability was increased to about 0.01 bp.
  • the product obtained by mismatch PCR was constructed into a vector containing the heavy chain constant region by homologous recombination.
  • a secondary library with a capacity of 1 ⁇ 107 was obtained under screening pressures including TIGIT antigen titer, competition with unlabeled antigen, and competition with parental antibody, three rounds of screening by FACS method, yeast expression Corresponding antibody.
  • the CDRL3 diversity gene was constructed into the CDRL1/CDRL2 gene library through homologous recombination to obtain a secondary library with a storage capacity of 1 ⁇ 10 7 , which was screened by one round of MACS and two rounds of FACS, and the yeast expressed the corresponding antibody.
  • antibody molecules ADI-55796 and ADI-55812 after affinity maturation were obtained.
  • the sequences and sequence numbers of ADI-55796 and ADI-55812 are shown in Table 1, wherein the CDRs are determined by the IMGT numbering system.
  • Tiragolumab is an anti-human TIGIT antibody from Genentech expressed by HEK293 cells, and its light and heavy chain variable region sequences are consistent with INN list 177NO 1918185-84-8 .
  • Transient expression and purification via the HEK293 expression system the specific operation is as follows: use the chemical transfection method to transfer the pcDNA3.1 vector carrying the antibody heavy chain and light chain into HEK293 cells, and culture at 37°C and 8% CO 2 7 days. The cell fluid was collected and centrifuged at 13000rpm for 20 minutes. Take the supernatant, Protein A purification supernatant, SEC to detect the purity of the antibody, while controlling the endotoxin content. Finally, antibodies ADI-55796-G1, ADI-55812-G1, ADI-55796-G1LALA, ADI-55812-G1LALA were obtained.
  • the antibodies ADI-55796-G1, ADI-55812-G1, ADI-55796-G1LALA, and ADI-55812-G1LALA obtained in Example 1 were combined with human, cynomolgus monkey, and mouse TIGIT using biofilm layer optical interference technology (ForteBio).
  • the binding dissociation constant (K D ) Fortebio affinity was determined according to existing methods (Este, P et al. High throughput solution-based measurement of antibody-antigen affinity and epitope binning. Mabs, 2013.5 (2): p.270-8), the human, cynomolgus monkey
  • the amino acid sequences of the extracellular segment of TIGIT and mouse are respectively shown in SEQ ID NO: 19-21.
  • the sensor is equilibrated offline for 20 minutes in the assay buffer, and then detected online for 120s to establish a baseline, and load the intact TIGIT antibody to the AHQ sensor to a thickness 1nm for affinity detection.
  • Antibody-loaded sensors were plateaued in 100 nM TIGIT-his antigen, then the sensors were transferred to assay buffer for at least 2 minutes for off-rate measurements.
  • Kinetic analysis was performed using a 1:1 binding model.
  • Anti-TIGIT clones ADI-55796 and ADI-55812 have high binding activity to human TIGIT and cynomolgus monkey TIGIT.
  • ADI-55796 also has cross-binding activity to mouse TIGIT.
  • Example 3 Binding activity and blocking activity of anti-TIGIT antibodies to overexpressed human/cynomolgus monkey/mouse TIGIT CHO cells
  • the pCHO1.0 vector purchased from Invitrogen
  • human TIGIT human TIGIT
  • cynomolgus TIGIT mouse TIGIT cDNA cloned into MCS was transfected to produce CHO-S cells (CHO-huTIGIT cells) overexpressing human TIGIT.
  • CHO-S cells overexpressing cynomolgus TIGIT
  • CHO-muTIGIT cells CHO-muTIGIT cells
  • the expanded cultured CHO-huTIGIT cells were adjusted to a cell density of 2 ⁇ 10 6 cells/mL, 100 ⁇ L/well was added to a 96-well flow plate, and centrifuged for later use. Dilute the purified monoclonal antibody with PBS, starting at 400nM and diluting 3 times for a total of 12 points. Add 60 ⁇ L/well of the diluted sample into the above-mentioned 96-well flow plate with cells, and incubate at 4°C for 30 minutes.
  • Example 4 Anti-TIGIT antibody binds to TIGIT on the surface of primary T cells
  • the binding activity of the invented anti-TIGIT antibody to TIGIT on the surface of activated T cells was detected based on the flow cytometry detection method.
  • human PBMCs were sorted according to the protocol provided by STEMCELL (stemcell, catalog number: #17951C) to obtain human total T cells.
  • Use X-VIVO15 medium (purchased from lonza, product number: 04-418Q) to adjust the concentration of T cells to 1.0 ⁇ 10 6 cells/mL, add 1 ⁇ L IL-2 stock solution (1 million IU), and simultaneously 1:1 (bead- to-cell) were added to CD3/CD28 Dynabeads (purchased from gibco, product number: 11132D), and cultured in a 5% CO 2 incubator at 37° C. for 48 hours.
  • the activated T cells were adjusted to a suitable cell density and added to a 96-well flow plate.
  • the samples to be tested were added in a gradient dilution and incubated at 4°C for 30 minutes. Wash twice with PBS, add corresponding fluorescent secondary antibody diluted to an appropriate concentration, incubate at 4°C for 30 minutes, wash twice with PBS. Add PBS to resuspend cells, detect on CytoFlex flow cytometer and calculate corresponding MFI.
  • Figure 6 the results show that the anti-TIGIT antibodies ADI-55796-G1, ADI-55796-G1LALA, ADI-55812-G1, ADI-55812-G1LALA of the present invention can bind TIGIT molecules on the surface of activated T cells, and the binding activity Outperformed the reference molecule Tiragolumab.
  • Embodiment 5 Luciferase reporter gene system detects anti-TIGIT antibody activity
  • a luciferase reporter gene system was constructed in this example.
  • cells were transfected with lentivirus to construct CHO-K1 overexpressing human CD155 and OKT-3 scFv Cell line (CHO-K1-CD155), a Jurkat cell line (Jurkat-TIGIT-luc) overexpressing human TIGIT and NF-AT luciferase reporter genes was constructed, and this reporter gene system was used to carry out related experiments.
  • the CHO-K1-CD155 functional cells were obtained by digestion, the cell density was adjusted, 100 ⁇ L/well was added to a 96-well white bottom plate, and the adherent culture was carried out overnight. On the second day, a Jurkat-TIGIT-luc effector cell suspension was prepared, and the test sample was serially diluted with a reaction medium (RPMI1640+10% FBS).
  • Example 6 Detection of synergistic effect of anti-TIGIT antibody and anti-PD-L1/PD-1 antibody by luciferase reporter gene system
  • this example constructed the following luciferase reporter gene system, briefly described as, on the basis of Example 5, slowly Virus infected CHO-K1-CD155 to overexpress CD122 and PD-L1 to obtain CHO-K1-CD155-CD112-PD-L1 functional cells, and lentivirus infected Jurkat-TIGIT-luc to overexpress PD-1 to obtain Jurkat-TIGIT- PD-1-luc effector cell suspension, and then use this reporter gene system to carry out related experiments.
  • CHO-K1-CD155-CD112-PD-L1 functional cells were obtained by digestion, the cell density was adjusted, 100 ⁇ L/well was added to a 96-well white bottom plate, and adherent culture was carried out overnight. The next day, a Jurkat-TIGIT-PD-1-luc effector cell suspension was prepared, and the samples to be tested (the anti-PD-1/PD-L1 antibodies used were Atezolizumab and Pembrolizumab) were serially diluted with the reaction medium.
  • Example 7 Detection of ADCC activity of anti-TIGIT antibody in vitro
  • the in vitro ADCC activity of the anti-TIGIT antibody of the present invention was detected.
  • Jurkat-NFAT-Luciferase-CD16ADCC effector cells purchased from Promega
  • the cells were resuspended to 4 ⁇ 10 6 cells/mL in 1640 medium containing 10% low IgG FBS.
  • the CT-26 cell tumor-bearing mouse model was established by subcutaneous inoculation.
  • the average tumor volume grew to 100-200mm, they were divided into groups , and treated with different doses of the anti-TIGIT antibody of the present invention by intraperitoneal injection.
  • the tumor volume and body weight of the mice in the group were monitored at a frequency of 2-3 days/time for 2 to 3 weeks, and the dosage and method of administration were shown in Table 4-5.
  • the results are shown in Figures 10A-B, and the results show that the anti-TIGIT antibody ADI-55796-G1 of the present invention can significantly inhibit the growth of tumors in mice in a dose-dependent manner.
  • Example 9 Study on the synergistic pharmacodynamics of anti-TIGIT antibody and anti-PD-L1 antibody in wild-type Balb/c mice
  • the CT-26 cell tumor-bearing mouse model was first established by subcutaneous inoculation, and grouped when the average tumor volume grew to 100-200 mm 3 , and the anti-TIGIT antibody and/or anti-PD-L1 antibody of the present invention were administered intraperitoneally.
  • (Atezolizumab) treatment monitor the changes in tumor volume and body weight of the mice in each group, the monitoring frequency is 2-3 days/time, continuous monitoring for 2 to 3 weeks, the dosage and method of administration are shown in Table 6. The results are shown in Figure 11.
  • the anti-TIGIT antibody ADI-55796-G1 of the present invention combined with the anti-PD-L1 antibody Atezolizumab had significantly better tumor inhibitory activity than the corresponding two mAb treatment groups. It is suggested that the anti-TIGIT antibody ADI-55796-G1 of the present invention can exert synergistic anti-tumor activity with the anti-PD-L1 antibody Atezolizumab in the wild-type mouse CT-26 model.
  • Example 10 Study on the synergistic pharmacodynamics of anti-TIGIT antibody and anti-PD-L1 antibody in huTIGIT KI mice
  • CT-26 tumor cells were transplanted into human TIGIT transgenic mice (huTIGIT KI mice) to determine the synergistic anti-tumor effect of the TIGIT antibody of the present invention and the anti-PD-L1 antibody.
  • the CT-26 tumor-bearing mouse model was first established by subcutaneous inoculation. When the average tumor volume grew to 80-120 mm 3 , they were divided into groups, treated with different antibodies and different doses by intraperitoneal injection, and the tumors of mice in each group were monitored. Volume and body weight changes, the monitoring frequency is 2-3 days/time, and continuous monitoring is 2 to 3 weeks.
  • the dosage and method of administration are shown in Table 7-8.
  • the results are shown in Figure 12A-B, the results show that the anti-TIGIT antibodies ADI-55796-G1, ADI-55796-G1LALA, and ADI-55812-G1 of the present invention are all effective in human TIGIT transgenic mice transplanted with CT-26 tumor cells. Synergistic antitumor activity was observed with the anti-PD-L1 antibody atezolizuamb.
  • Table 7 Dosing regimen of anti-TIGIT antibody and anti-PD-L1 antibody (corresponding to Figure 12A)
  • Table 8 Dosing regimen of anti-TIGIT antibody and anti-PD-L1 antibody (corresponding to Figure 12B)
  • Example 11 Study on synergistic pharmacodynamics of anti-TIGIT antibody and anti-PD-L1 antibody in B-NDG mice inoculated with A375 and human PBMC in vivo
  • B-NDG mice were inoculated with A375 (purchased from Addexbio, article number: C0020004) and human PBMC cells (Shanghai Miaoshun, A10S033014/PB100C) to determine the synergistic anti-PD-L1 antibody of the present invention. tumor effect.
  • A375 and human PBMC tumor-bearing mouse models were established by subcutaneous mixed inoculation. When the average tumor volume grew to about 200 mm 3 , they were divided into groups, treated with different antibodies and different doses by intraperitoneal injection, and the mice in each group were monitored. For changes in tumor volume and body weight, the monitoring frequency was 2-3 days/time, and the monitoring was continuous for 2 to 3 weeks.
  • the dosage and method of administration are shown in Table 9.
  • Table 9 Synergistic administration regimen of anti-TIGIT antibody and anti-PD-L1 antibody A375 model
  • mice The half-life of the anti-TIGIT antibody of the present invention in mice was detected by a single tail vein injection method.
  • Balb/c mice were used in the experiment, half male and half male, 12/12 hours light/dark adjustment, temperature 24 ⁇ 2°C, humidity 40-70%, free access to water and diet.
  • Balb/c mice were injected with a single monoclonal antibody molecule into the tail vein, and the injection dose was 10 mg/kg.
  • Blood collection time point 5 minutes, 0.5 hours, 2 hours, 6 hours, 24 hours, 48 hours, 96 hours, 168 hours, 336 hours, and 504 hours after administration, blood was collected from the mouse orbit.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Optics & Photonics (AREA)
  • Tropical Medicine & Parasitology (AREA)
PCT/CN2022/111145 2021-08-09 2022-08-09 抗tigit抗体及其用途 Ceased WO2023016450A1 (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP22855431.7A EP4386003A1 (en) 2021-08-09 2022-08-09 Anti-tigit antibody and use thereof
US18/682,325 US20240352118A1 (en) 2021-08-09 2022-08-09 Anti-tigit antibody and use thereof
KR1020247007621A KR20240043786A (ko) 2021-08-09 2022-08-09 항-tigit 항체 및 이의 용도
CA3228504A CA3228504A1 (en) 2021-08-09 2022-08-09 Anti-tigit antibody and use thereof
AU2022327511A AU2022327511A1 (en) 2021-08-09 2022-08-09 Anti-tigit antibody and use thereof
CN202280054124.0A CN117794952A (zh) 2021-08-09 2022-08-09 抗tigit抗体及其用途
JP2024508052A JP2024533993A (ja) 2021-08-09 2022-08-09 抗ｔｉｇｉｔ抗体およびその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110907583.6 2021-08-09
CN202110907583 2021-08-09

Publications (1)

Publication Number Publication Date
WO2023016450A1 true WO2023016450A1 (zh) 2023-02-16

Family

ID=85199833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/111145 Ceased WO2023016450A1 (zh) 2021-08-09 2022-08-09 抗tigit抗体及其用途

Country Status (8)

Country Link
US (1) US20240352118A1 (https=)
EP (1) EP4386003A1 (https=)
JP (1) JP2024533993A (https=)
KR (1) KR20240043786A (https=)
CN (1) CN117794952A (https=)
AU (1) AU2022327511A1 (https=)
CA (1) CA3228504A1 (https=)
WO (1) WO2023016450A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4435010A4 (en) * 2021-11-17 2025-11-19 Biotheus Inc Bispecific antibody against TIGIT and PD-L1, its pharmaceutical composition and use

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
WO2010105256A1 (en) 2009-03-13 2010-09-16 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
WO2012009568A2 (en) 2010-07-16 2012-01-19 Adimab, Llc Antibody libraries
CA3042727A1 (en) * 2016-11-19 2018-05-24 Potenza Therapeutics, Inc. Anti-gitr antigen-binding proteins and methods of use thereof
CN112135626A (zh) * 2018-07-25 2020-12-25 信达生物制药(苏州)有限公司 抗tigit抗体及其用途
US20200407445A1 (en) * 2017-07-27 2020-12-31 Iteos Therapeutics Sa Anti-tigit antibodies
CN112274637A (zh) * 2016-08-17 2021-01-29 康姆普根有限公司 抗tigit抗体、抗pvrig抗体及其组合
CN112794909A (zh) * 2021-02-04 2021-05-14 广州爱思迈生物医药科技有限公司 一种抗tigit单克隆抗体及其应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
WO2010105256A1 (en) 2009-03-13 2010-09-16 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
WO2012009568A2 (en) 2010-07-16 2012-01-19 Adimab, Llc Antibody libraries
CN112274637A (zh) * 2016-08-17 2021-01-29 康姆普根有限公司 抗tigit抗体、抗pvrig抗体及其组合
CA3042727A1 (en) * 2016-11-19 2018-05-24 Potenza Therapeutics, Inc. Anti-gitr antigen-binding proteins and methods of use thereof
US20200407445A1 (en) * 2017-07-27 2020-12-31 Iteos Therapeutics Sa Anti-tigit antibodies
CN112135626A (zh) * 2018-07-25 2020-12-25 信达生物制药(苏州)有限公司 抗tigit抗体及其用途
CN112794909A (zh) * 2021-02-04 2021-05-14 广州爱思迈生物医药科技有限公司 一种抗tigit单克隆抗体及其应用

Non-Patent Citations (37)

* Cited by examiner, † Cited by third party
Title
ALFTHAN ET AL., PROTEIN ENG., vol. 8, 1995, pages 725 - 731
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81
BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 - 1187
BURKS ET AL., PROC. NATL ACAD. SET USA, vol. 94, 1997, pages 412 - 417
CARTER ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167
CHOI ET AL., EUR. J. IMMUNOL., vol. 31, 2001, pages 94 - 106
CHOTHIA ET AL., NATURE, vol. 341, 1989, pages 544 - 546
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
DAVIES ET AL., ANNUAL REV BIOCHEM, vol. 59, 1990, pages 439 - 473
ESTE, P ET AL.: "High throughput solution-based measurement of antibody-antigen affinity and epitope binning", MABS, vol. 5, no. 2, 2013, pages 270 - 8, XP055105281, DOI: 10.4161/mabs.23049
F. M. AUSUBEL ET AL.: "Compiled Laboratory Guide to Molecular Biology", 1995, JOHN WILEY & SONS, INC.
GE, ZHOUHONG ET AL.: "TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer", FRONTIERS IN IMMUNOLOGY, vol. 12, 22 July 2021 (2021-07-22), XP055973881, DOI: 10.3389/fimmu.2021.699895 *
GUILLEREY CHARJUNPAA HCARRIE N ET AL.: "TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma", BLOOD, vol. 132, 2018, pages 1689 - 1694, XP086685467, DOI: 10.1182/blood-2018-01-825265
HOLLIGER ET AL., NAT BIOTECHNOL, vol. 23, 2005, pages 1126 - 1136
HOLLIGER P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
HU ET AL., CANCER RES., vol. 56, 1996, pages 3055 - 3061
HUDSON, CURR. OPIN. IMMUNOL., vol. 11, 1999, pages 548 - 557
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
J. SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
JOHNSTON ROBERT J.; COMPS-AGRAR LAETITIA; HACKNEY JASON; YU XIN; HUSENI MAHRUKH; YANG YAGAI; PARK SUMMER; JAVINAL VINCENT; CHIU HE: "The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+T Cell Effector Function", CANCER CELL, vol. 26, no. 6, 26 November 2014 (2014-11-26), US , pages 923 - 937, XP029111576, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2014.10.018 *
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE
KARLINALTSCHUL, PROC. NATL. ACAD. SCI. U.S.A., vol. 87, 1990, pages 2264 - 2268
KARLINALTSCHUL, PROC. NATL. ACAD. SCI. U.S.A., vol. 90, 1993, pages 5873 - 5877
KIPRIYANOV ET AL., J. MOL. BIOL., vol. 293, 1999, pages 41 - 56
KOBAYASHI ET AL., PROTEIN ENG., vol. 12, no. 10, 1999, pages 879 - 884
KURTULUS SSAKUISHI KNGIOW SF ET AL.: "TIGIT predominantly regulates the immune response via regulatory T cells", J CLIN INVEST., vol. 125, no. 11, 2 November 2015 (2015-11-02), pages 4053 - 62, XP055708798, DOI: 10.1172/JCI81187
LEFRANC ET AL., DEV. COMPARAT. IMMUNOL., vol. 27, 2003, pages 55 - 77
LITTLE ET AL., IMMUNOL. TODAY, vol. 21, 2000, pages 364 - 370
MALMQVIST M, NATURE, vol. 361, 1993, pages 186 - 187
MORIMOTO ET AL., J. BIOCHEM. BIOPHYS. METHODS, vol. 24, 1992, pages 107 - 117
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
POLJAK R. J. ET AL., STRUCTURE, vol. 113, 1994, pages 1121 - 1123
ROOVERS ET AL., CANCER IMMUNOL, 2001
ZHANG QBI JZHENG X ET AL.: "Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity", NAT IMMUNOL., vol. 19, no. 7, July 2018 (2018-07-01), pages 723 - 732, XP036533618, DOI: 10.1038/s41590-018-0132-0
ZHU LINXIAO, LI YOULUN: "Clinical Research Status of Immune Checkpoint Inhibitors in the Treatment of Small Cell Lung Cancer", JOURNAL OF CLINICAL PULMONARY MEDICINE, vol. 25, no. 5, 23 April 2020 (2020-04-23), pages 788 - 793, XP093034251, ISSN: 1009-6663 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4435010A4 (en) * 2021-11-17 2025-11-19 Biotheus Inc Bispecific antibody against TIGIT and PD-L1, its pharmaceutical composition and use

Also Published As

Publication number Publication date
JP2024533993A (ja) 2024-09-18
AU2022327511A1 (en) 2024-03-07
EP4386003A1 (en) 2024-06-19
CA3228504A1 (en) 2023-02-16
US20240352118A1 (en) 2024-10-24
KR20240043786A (ko) 2024-04-03
CN117794952A (zh) 2024-03-29

Similar Documents

Publication Publication Date Title
CN113166246A (zh) 一种抗体及其用途
CN110462038A (zh) 抗gprc5d抗体和包含所述抗体的分子
CN115043942A (zh) Ror1结合蛋白及其用途
JP2023550832A (ja) ＣＤ３９およびＴＧＦβを標的とする新規のコンジュゲート分子
US20250297009A1 (en) Anti-pd-1 monoclonal antibody, derivative thereof and use thereof
TW202421666A (zh) B7-h3結合蛋白及其用途
US12258400B2 (en) Antibodies having specificity for BTN2 and uses thereof
WO2023186121A1 (en) Anti-cd39 nanobody and uses thereof
WO2024094003A1 (zh) 抗ccr8的抗体及其用途
US20240352118A1 (en) Anti-tigit antibody and use thereof
WO2024061224A1 (zh) 抗her2抗体及其用途
JP2025512671A (ja) Ｈｅｒ３結合タンパク質及びその使用
CN117586398A (zh) 抗tigit抗体及其用途
EP4538288A1 (en) Anti-cd40 antibody and use thereof
WO2025190376A1 (zh) 抗cd161抗体及其用途
WO2025190375A1 (zh) 抗cd161抗体及其用途
HK40048164A (en) Antibody and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22855431

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280054124.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2024508052

Country of ref document: JP

Ref document number: 3228504

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2022327511

Country of ref document: AU

Ref document number: AU2022327511

Country of ref document: AU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024002596

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2022327511

Country of ref document: AU

Date of ref document: 20220809

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022855431

Country of ref document: EP

Effective date: 20240311

ENP Entry into the national phase

Ref document number: 112024002596

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240208